Evidence map›Paper›PMID 40701985›Full record

Trial reportRenal failure2025

Ticagrelor versus clopidogrel in

Yu Wu, Yilun Zhou, Yuesong Pan, Aoming Jin, Xia Meng, Hao Li, Yilong Wang, Yong Jiang, Yongjun Wang

Abstract readRandomized Controlled TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu WuDepartment of Nephrology, BeijingTiantan Hospital, Capital Medical University, Beijing, China.
Yilun ZhouDepartment of Nephrology, BeijingTiantan Hospital, Capital Medical University, Beijing, China.
Yuesong PanChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Aoming JinChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Xia MengChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Hao LiChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Yilong WangChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Yong JiangChina National Clinical Research Center for Neurological Diseases, Beijing, China.
Yongjun WangChina National Clinical Research Center for Neurological Diseases, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the efficacy and safety of ticagrelor versus clopidogrel in stroke patients who were

methodsPatients in the CHANCE-2 trial were randomized to ticagrelor-aspirin or clopidogrel-aspirin treatment. The primary efficacy outcome was occurrence of a new stroke within 90 days, while bleeding was assessed for safety. Patients were categorized based on age and estimated glomerular filtration rate (eGFR).

resultsIn patients with eGFR >90 mL/min/1.73 m

conclusionsElderly patients with normal renal function appear to benefit from ticagrelor compared with clopidogrel. Both younger patients with normal renal function and those with advanced age and renal insufficiency are prone to mild bleeding.

Indexed as

ClopidogrelCytochrome P-450 CYP2C19Ischemic Attack, TransientPlatelet Aggregation InhibitorsStrokeTicagrelorAgedAge FactorsAspirinDrug Therapy, CombinationFemaleGlomerular Filtration RateHemorrhageHumansLoss of Function MutationMaleAspirinClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsTicagrelorageclopidogrelrenal functionstrokeTicagrelor

Identifiers

PMID40701985
PMCPMC12288173

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.